Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8754497 | 0.94 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPK1CACNA2D1CACNB3 | |
| SCHEMBL171394 | 0.86 | TRPM8 (0.30) | — | |
| SCHEMBL20755809 | 0.86 | PIK3CD (0.30) | — | |
| SCHEMBL21025063 | 0.84 | TSHR (0.38) | TSHRCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL22198561 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHRCA2 | |
| SCHEMBL9743519 | 0.75 | HTR2A (0.36) | — | |
| SCHEMBL24892891 | 0.75 | — | — | |
| SCHEMBL13412952 | 0.75 | TSHR (0.33) | ALDH1A1TSHRMAPK1ADRA1ACA12 | |
| SCHEMBL12039746 | 0.75 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL23969637 | 0.73 | HTR2A (0.33) | ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | ALDH1A1 4468/4885TSHR 823/4885MAPK1 3271/4885 |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | ALDH1A1 900/4885TSHR 1282/4885MAPK1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.